Overview
Human Biome is focused on research related to the gut microbiome and aims to create next-generation biotherapeutics for more effective disease treatment and health restoration. The company combines science and technology in its projects, which include a microbiota bank.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
News
Human Biome S.A. received financial support under the European Funds for the Modern Economy
Human Biome S.A. secures 2nd tranche in Series A round
We close the first tranche of round A and raise 4 million USD for biosynthetic microbiome development!
Human Biome S.A. received financial support under the European Funds for the Modern Economy
Human Biome Institute in the Top Disruptors in Healthcare Report
Industry
Bank accounts
Registered as a VAT taxpayer on 2020-03-20. Active
06 1050 1764 1000 0090 8611 2555- 71 1050 1764 1000 0090 8632 5561
- 86 1050 1764 1000 0090 8265 0640
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Dec 1, 2022 | Transformation registered |
Public aid
4 public aid cases recorded, with a total value of $4,743,832.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Feb 25, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | —— | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Nov 20, 2025 | Aid for research and development projects: industrial research | —— | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Nov 20, 2025 | Aid for research and development projects: experimental development | —— | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2026-01-01 | Opracowanie zaawansowanej formulacji FMT – ekobiotyku zawierającego skoncentrowaną i utrwaloną ludzką mikrobiotę jelitową z macierzą zewnątrzkomórkową dla zwiększonej stabilności, przeżywalności i skuteczności w terapii zakażeń CDI | $6.5M$6,511,122 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2025-09-01 | Przygotowanie wniosku o Eurogrant planowanego do realizacji w ramach programu EIC pre-accelerator - Widening | $17,431$17,431 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2022-02-01 | Przygotowanie dokumentacji aplikacyjnej dla projektu o roboczej nazwie: „Opracowanie Bioterapeutyku Nowej Generacji na bazie składowych mikrobioty jelitowej do walki z antybiotykoopornością drobnoustrojów” planowanego do realizacji w ramach programu EIC Pathfinder Open | $5,215$5,215 | Program Operacyjny Inteligentny Rozwój |
Tenders
20 tenders recorded as contractor: 10 national ($655,894) and 10 EU ($23,824,173).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Sep 4, 2026 | Usługa przetworzenia kału w celu transferu mikrobioty jelitowej | —— | Samodzielny Publiczny Zakład Opieki Zdrowotnej Uniwersytecki Szpital Kliniczny Nr 1 Im. Norberta Barlickiego Uniwersytetu Medycznego w Łodzi | |
| Aug 10, 2026 | "Sukcesywne dostawy produktów farmaceutycznych do Wojewódzkiego Szpitala Zespolonego w Kaliszu" | $776.1K$776,129 | Wojewódzki Szpital Zespolony Im. Ludwika Perzyny w Kaliszu | |
| Jul 24, 2026 | Dostawa leków, środków spożywczych specjalnego przeznaczenia żywieniowego, surowców recepturowych - 27 pakietów. | $830.9K$830,854 | Szpital Kliniczny Im. Karola Jonschera Uniwersytetu Medycznego Im. Karola Marcinkowskiego w Poznaniu |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a one-person management board, the sole member of the management board is entitled to make declarations of will concerning the company’s rights and obligations on behalf of the company. In the case of the appointment of a multi-member management board, each member of the management board is entitled to make declarations of will concerning the company’s rights and obligations on behalf of the company independently.
Supervisory board
Beneficial owners
| Person | Rights | |
|---|---|---|
Jarosław Józef Biliński (40)  | Shareholder of a joint-stock company, 37.52% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| PoltregS.A. | $1,906,011.66 | poltreg.com | ||
| Natur DayS.A. | $680,635.59 | naturday.pl | ||
| Biotriosp. z o.o. | $453,662.22 | biotrio.pl | ||
| F1 PharmaS.A. | $272,113.66 | f1pharma.pl | ||
| Ti-Comsp. z o.o. | $157,549.77 | ticomglobal.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-08-26 | Share capital change (142,169.50 PLN → 160,774.20 PLN) | |
| 2026-03-26 | Share capital change (123,564.90 PLN → 142,169.50 PLN) | |
| 2025-07-17 | Name change (Human Biome Institute → Human Biome) | |
| 2025-02-04 | Share capital change (116,300.00 PLN → 123,564.90 PLN) | |
| 2023-09-21 | Share capital change (110,500.00 PLN → 116,300.00 PLN) |
FAQ
Last updated: 2026-08-26